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Analysis of the p53 gene in human choriocarcinoma cell lines
Y Yaginuma, T Yamashita, N Takuma, H Katayama and M Ishikawa
Department of Obstetrics and Gynecology, Asahikawa Medical College, Asahikawa, Japan.
Summary In the present study. we analysed human choriocarcinoma cell lines for abnormalities in the
tumour-suppressor gene p53 by Southern blotting, Northern blotting, non-radioisotopic single-stranded con-
formational polymorphism (SSCP) and complementary DNA sequencing. In all cell lines (Bewo, GCH-1,
GCH-2. SCH, JAR, JEG-3. NUC-1 and HCCM-5), no p53 gene abnormality was detected by using Southern
blotting. p53 mRNA of the expected size was detected in all cell lines tested by Northern blotting. SSCP
analysis revealed abnormalities of p53 cDNA in the SCH cell line. Sequencing analysis of the entire coding
region of the p53 gene revealed that both alleles were expressed in the JEG-3 cell line, and one of the alleles
contained a point mutation (G to T) in codon 167 (Gln to His). In the NUC-1 cell line both alleles were point
mutated. One allele had a point mutation (A to T) that resulted in a codon 17 change (Glu to Asp), and
another had a point mutation (A to T) that caused a codon 24 change (Lys to Asn). In the SCH cell line,
AGG was inserted between codon 249 and 250; this insertion resulted in an abnormal structure of the p53
protein. In three out of eight human choriocarcinoma cell lines, a p53 gene abnormality was detected.
Therefore our data demonstrate that p53 gene abnormalities are associated with choriocarcinoma cell lines.
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Choriocarcinoma is very malignant, and is frequently metas-
tatic. The 30 year incidence of gestational choriocarcinoma is
2.46 cases per 100 000 pregnancies. There is an increased risk
among women older than 45 years. Non-whites have an
approximately 2-fold increased risk of gestational choriocar-
cinoma compared with whites (Buckley et al., 1984). In
Japan at present it is very difficult to obtain specimens of
choriocarcinoma for study. Therefore we investigated human
choriocarcinoma cell lines.
Genetic analysis of human tumours strongly suggests that
a number of gene defects accumulate over time and interact
to bring about derangement of growth control that ultimately
results in malignancy (Bishop et al., 1991; Hollingsworth
and Lee, 1991). Increasing evidence supports the
hypothesis that the p53 gene acts as a tumour-suppressor
gene (Baker et al.. 1990; Strech et al., 1991), and mutations
of the p53 gene are frequently found in a variety of cancers
(Rodriguez et al.. 1990; Davidoff et al., 1991). Recently,
oncogene activation and tumour-suppressor gene inactivation
have been reported in some human gynaecological tumours
(Yaginuma and Westphal, 1991, 1992; Yaginuma et al.,
1993), but in choriocarcinoma this has not been analysed
previously. Therefore, in the present study, we used
molecular biology techniques to analyse p53 gene abnor-
malities in human choriocarcinoma cell lines.
Materials and methods
Cell lines
In this study we used eight choriocarcinoma cell lines (Bewo
from Dr Pattillo, Wisconsin University; GCH-1 and GCH-2
from Dr Tanaka, Niigata University; SCH, JAR and JEG-3
from Dr Sekiya, Chiba University; NUC-1 from Dr
Suzumori, Nagoya City University; HCCM-5 from Dr Itoh,
Jikei Medical College).
Southern blot analysis
High molecular weight genomic DNAs were extracted using
a published proteinase K/phenol protocol (Mamnatis et al..
1989), and human placental DNA was used as the control.
DNA samples were digested with restriction endonucleases as
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directed by the supplier. Digested DNA samples (10 gg) were
separated by electrophoresis on 0.8% agarose gels and trans-
ferred to a nylon membrane. Membranes were hybridised
with 32P-labelled p53 probes. The plasmid phpS3c-1 contain-
ing the p53 complementary DNA was kindly supplied by Dr
M Oren (Zakut-Houri et al., 1985). The 1.9 kb fragment of
php53c-1, including the entire p53-coding region, was used as
a probe. This fragment was labelled with [a-32PJdCTP using
the Random Primer Kit (Stratagene).
RNA isolation and Northern blot analysis
Total RNA was extracted from cells by the guanidinium
thiocyanate extraction procedure (Ausubel et al., 1989). Total
placental RNA was used as a control. Samples (20 Lg) were
denatured with 6.3% formaldehyde and 50% formamide,
subjected to electrophoresis on a 1% agarose gel, transferred
to a nylon membrane and hybridised with the labelled p53
probe.
Non-radioisotopic poltmerase chain reaction (PCR)-SSCP
andsequencing ofthe entire coding region ofthe p53 cDNA
Non-radioisotopic PCR-SSCP was accomplished according
to an adapted version of a previously reported method (Reiss
et al., 1992; Imamura et al., 1993; Marchetti et al., 1993).
Electrophoresis was carried out in a non-denaturing 10-20%
gradient gel (polyacrylamide gel) at 4'C, and PCR products
were separated with 100 V constant voltage, following silver
staining to visualise the bands.
Complementary DNA was generated from total RNA
using 200 units of the Molony strain of murine leukaemia
virus reverse transcriptase (BRL) with oligo(dT) as a primer.
A 1.3 kb fragment including the entire p53-coding region was
generated from the complementary DNA by PCR. Sequenc-
ing of the entire p53-coding region was performed as
reported previously (Yaginuma and Westphal, 1991).
Fragments containing the entire p53-cding region were
amplified by mixing 5' primer (AAGC(-l CCACGACG-
GTGACACGCTTC) and 3' primer (GAATTCCGCACA
CCTATTGCAAGCAAGG), 1.5 mM magnesium chloride,
50 mM potassium chloride, 0.2 mM deoxyribonucleotide tri-
phosphate, 2.5 units of Taq polymerase and 10 mM Tris-
HC1 (pH 8.3). For amplification, we used 35 cycles of 94'C
denaturation (1.5 min), 65'C annealing (1.5 min) and 72°C
extension (2 min) in an automated Perkin-Elmer Cetus ther-
mal cycler. The 5' primer was fitted with HindII sites and
the 3' primer with EcoRI sites to facilitate cloning. PCRml Anaysis d the p53 gene in human chiocinonm cell kis
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product was digested with HindIIl and EcoRI and subcloned
into HindIII-EcoRI-digested PGEM-3Z. More than 100 col-
onies were used as templates in the sequencing reaction.
Results
Southern blot analysis ofthe p53 gene
High molecular weight genomic DNA prepared from individ-
ual cell lines was digested with restriction enzymes HindlII,
PvuII and BamHI and electrophoresed on a 0.8% agarose
gel. Compared with the control, an aberrant restriction pat-
tern was not detected in any cell lines tested (Figure 1),
suggesting that no gross rearrangement of the p53 gene locus
exists in any of the cell lines.
Northern blot analysis
Expression of the p53 gene in the various tumour cell lines
was examined by Northern blot analysis of total RNA. A
human y-actin probe served as an internal control for possi-
ble variations in the amount of RNA loaded from each
sample. As seen in Figure 2, all the cell lines contained
readily detectable levels of 2.5 kb p53-specific mRNA. In
these cell lines there is no overexpression compared with the
normal placental p53 mRNA, while in the GCH-2, JAR, and
NUC-1 cell lines only one weak band is visible.
Non-radioisotopic PCR-SSCP and sequence analysis ofthe
entire p53 coding region
We screened for abnormalities of p53 cDNA by using non-
radioisotopic SSCP. SSCP analysis revealed abnormalities of
p53 cDNA in the SCH (Figure 3) cell line. The p53 gene is
found to be mutated in a wide variety of human tumours.
The most common types of abnormalities are small deletions
and point mutations that alter the genetic code and, hence.
the amino acid sequence of the p53 peptide chain. Such
subtle gene alterations may well escape detection by Southern
blot and Northern blot and SSCP is an imperfect method of
detecting gene abnormalities. In order to assess the
prevalence of such gene alterations in choriocarcinoma cell
lines, we sequenced the entire coding region of p53 present in
transcripts of all tumour cell lines. The results obtained with
the choriocarcinoma cell lines are summarised in Table I.
Sequencing analysis of the entire coding region of the p53
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Figure 2 Northern blot analysis of p53mRNA (20 tLg per lane)
in total cell extracts. The blot was probed with the XbaI fragment
of php53c-1 DNA. The positions of 28S and 18S rRNA and of
p53 mRNA markers are indicated. A human 7-actin probe was
used to ascertain that similar amounts of total RNA had been
loaded in each lane.
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Figue 1 Southern blot analysis of genomic DNA from human
placenta (control) and from human choriocarcinoma cell lines.
Each lane contains 1Oilg of HindII digest. The blot was probed
with the XbaI fragment of php53c-1 DNA.
Figre 3 Reverse transcription (RT)-SSCP analysis in SCH cell
line and placenta (control). Bands were visualised by silver stain-
ing. An arrow indicates extra bands only in SCH cell line.
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Table I p53 gene abnormalities in human choriocarcinoma cell lines
Cell line Mutation or insertion Codon Amino acid change
Bewo WrT
GCH-I WT
GCH-2 WVT
SCH AGG insertion Between 249 and 250 Arg insertion
JAR WIT
JEG-3 WT CAG to CAT 167 Gln to His
NUC-1 GAA to GATAAA to AAT 17 and 24 Glu to Asp Lys to Asn
HCCM-5 WT
G _AT G A TC
_AT GA_
A
- G insertion
G
SCH Wt.
Fire 4 Sequence analysis of p53 abnormal loci in the SCH cell
line. The templates used for the sequencing reactions consisted of
a mixture of more than 100 plasmids clones generated from PCR
product. Left: The SCH cell line showing a AGG insertion
between codons 249 and 250. Right: wild-type sequence.
gene revealed that both alleles were expressed in the JEG-3
cell line, and one of the alleles contained a point mutation (G
to T) in codon 167 (Gln to His). In the NUC-l cell line both
alleles were point mutated. One allele had a point mutation
(A to T) that resulted in a codon 17 change (Glu to Asp),
and other had a point mutation (A to T) that caused a codon
24 change (Lys to Asn). In the SCH cell line, AGG was
inserted between codons 249 and 250 (Figure 4); this inser-
tion resulted in addition of arginine to the normal p53 pro-
tein. In three out of eight human choriocarcinoma cell lines,
a p53 gene abnormality was detected. Therefore our data
show that p53 gene abnormalities are associated with
choriocarcinoma cell lines.
Our studies demonstrate that p53 gene abnormalities are
associated with cells derived from human chonrocarcinoma.
Our studies revealed mutations or insertions of the p53 gene
that lead to codon changes in three of the eight choriocar-
cinoma cell lines tested. The point mutations of two cell lines
that we detected did not involve G:C to A:T transitions to
CpG sites that are known hotspots for p53 gene mutations in
human tumours. This is attributed to deamination of methyl-
cytosine. Because CpG dinucleotides are likely to be
methylated, spontaneous deamination of 5-methylcytosine
residues might lead to such a mutation (Jones and Backley,
1990; Rideout et al., 1990). Our sequencing gels reveal
evidence for the presence of a wild-type allele in these two
lines, suggesting that both p53 alleles were expressed. In the
JEG-3 cell line one of the point mutations is in the highly
conservative region I. Abnormality of this region has not
been reported frequently. In line SCH, AGG insertion
resulted in the addition of arginine between codons 249 and
250. This position is located in the highly conservative region
IV. The carcinogenesis of choriocarcinoma is quite unique
compared with other human carcinomas, but at least some
choriocarcinomas are associated with abnormality of the p53
gene. However, it should be noted that our studies have been
performed on cell lines derived from human choriocar-
cinomas. Further investigations on primary tumours will be
necessary to define the relationship between p53 abnor-
malities and carcinogenesis of choriocarcinomas.
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